Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study

M. Senni, R. Wachter, KK. Witte, E. Straburzynska-Migaj, J. Belohlavek, C. Fonseca, C. Mueller, E. Lonn, A. Chakrabarti, W. Bao, A. Noe, H. Schwende, D. Butylin, D. Pascual-Figal, TRANSITION Investigators

. 2020 ; 22 (2) : 303-312. [pub] 20191209

Language English Country Great Britain

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21020771

Grant support
NIHR-CS-012-032 Department of Health - United Kingdom
Novartis - International

AIMS: Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM-HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER-HF and TRANSITION). However, data are lacking for the initiation of sacubitril/valsartan in newly diagnosed (de novo) HFrEF. Here, we assess the tolerability of initiating sacubitril/valsartan following ADHF in TRANSITION subgroups of patients with a de novo vs. prior diagnosis of HFrEF. METHODS AND RESULTS: TRANSITION randomised 1002 patients to pre- and post-discharge initiation of sacubitril/valsartan (analysis set n = 991, following exclusions for mis-randomisation). In this post-hoc analysis, tolerability to sacubitril/valsartan [proportion of patients achieving target dose (97/103 mg b.i.d.) at 10 weeks post-randomisation], adverse events (AEs) and serious AEs (SAEs) were compared in de novo (n = 286) and prior HFrEF (n = 705) subgroups. More de novo than prior HFrEF patients achieved target dose at Week 10 (56% vs. 45%; relative risk ratio 1.30, 95% confidence interval 1.12-1.52, P < 0.001), and fewer had SAEs and permanent treatment discontinuations. Initiation of sacubitril/valsartan did not prevent the concomitant initiation and up-titration of guideline-directed HF therapies. De novo patients showed faster and greater decreases in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin-T, and lower rates of HF and all-cause rehospitalisation vs. prior HFrEF. CONCLUSIONS: After ADHF, first-line initiation of sacubitril/valsartan in de novo HFrEF, alongside the initiation of other guideline-directed therapies, is feasible and is associated with a better risk-benefit profile than in patients with prior HFrEF. Early intervention with sacubitril/valsartan may be considered to delay disease progression in patients with de novo HFrEF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02661217.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020771
003      
CZ-PrNML
005      
20210830102422.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.1670 $2 doi
035    __
$a (PubMed)31820537
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Senni, Michele $u Cardiology Division, Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy
245    10
$a Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study / $c M. Senni, R. Wachter, KK. Witte, E. Straburzynska-Migaj, J. Belohlavek, C. Fonseca, C. Mueller, E. Lonn, A. Chakrabarti, W. Bao, A. Noe, H. Schwende, D. Butylin, D. Pascual-Figal, TRANSITION Investigators
520    9_
$a AIMS: Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM-HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER-HF and TRANSITION). However, data are lacking for the initiation of sacubitril/valsartan in newly diagnosed (de novo) HFrEF. Here, we assess the tolerability of initiating sacubitril/valsartan following ADHF in TRANSITION subgroups of patients with a de novo vs. prior diagnosis of HFrEF. METHODS AND RESULTS: TRANSITION randomised 1002 patients to pre- and post-discharge initiation of sacubitril/valsartan (analysis set n = 991, following exclusions for mis-randomisation). In this post-hoc analysis, tolerability to sacubitril/valsartan [proportion of patients achieving target dose (97/103 mg b.i.d.) at 10 weeks post-randomisation], adverse events (AEs) and serious AEs (SAEs) were compared in de novo (n = 286) and prior HFrEF (n = 705) subgroups. More de novo than prior HFrEF patients achieved target dose at Week 10 (56% vs. 45%; relative risk ratio 1.30, 95% confidence interval 1.12-1.52, P < 0.001), and fewer had SAEs and permanent treatment discontinuations. Initiation of sacubitril/valsartan did not prevent the concomitant initiation and up-titration of guideline-directed HF therapies. De novo patients showed faster and greater decreases in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin-T, and lower rates of HF and all-cause rehospitalisation vs. prior HFrEF. CONCLUSIONS: After ADHF, first-line initiation of sacubitril/valsartan in de novo HFrEF, alongside the initiation of other guideline-directed therapies, is feasible and is associated with a better risk-benefit profile than in patients with prior HFrEF. Early intervention with sacubitril/valsartan may be considered to delay disease progression in patients with de novo HFrEF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02661217.
650    _2
$a následná péče $7 D000359
650    _2
$a aminobutyráty $x terapeutické užití $7 D000613
650    _2
$a bifenylové sloučeniny $x terapeutické užití $7 D001713
650    _2
$a fixní kombinace léků $7 D004338
650    12
$a srdeční selhání $x farmakoterapie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a propuštění pacienta $7 D010351
650    _2
$a valsartan $x terapeutické užití $7 D000068756
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wachter, Rolf $u Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany $u Clinic for Cardiology and Pneumology, University Medicine Göttingen, Germany and German Cardiovascular Research Center, partner site Göttingen, Göttingen, Germany
700    1_
$a Witte, Klaus K $u Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
700    1_
$a Straburzynska-Migaj, Ewa $u 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland
700    1_
$a Belohlavek, Jan $u General Teaching Hospital, Charles University in Prague, Prague, Czech Republic
700    1_
$a Fonseca, Candida $u Heart Failure Unit, Internal Medicine Department, Hospital de São Francisco Xavier, CHLO, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
700    1_
$a Mueller, Christian $u University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Lonn, Eva $u McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
700    1_
$a Chakrabarti, Arhit $u Novartis Pharmaceuticals, Hyderabad, India
700    1_
$a Bao, Weibin $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Noe, Adele $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Schwende, Heike $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Butylin, Dmytro $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Pascual-Figal, Domingo $u Cardiology Department, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
710    2_
$a TRANSITION Investigators
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 22, č. 2 (2020), s. 303-312
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31820537 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102422 $b ABA008
999    __
$a ok $b bmc $g 1691364 $s 1141217
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 22 $c 2 $d 303-312 $e 20191209 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
GRA    __
$a NIHR-CS-012-032 $p Department of Health $2 United Kingdom
GRA    __
$p Novartis $2 International
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options